Peer-reviewed veterinary case report
Vinorelbine treatment outcomes for malignant tumors in 58 dogs
By Wouda, Raelene M et al.·Published in Journal of the American Veterinary Medical Association·2015·Department of Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997-2012).
- Species:
- dog
Plain-English summary
A group of 58 dogs with various types of cancer, including lung cancer and mast cell tumors, were treated with a chemotherapy drug called vinorelbine. Most of these dogs received vinorelbine to help manage their symptoms rather than as a cure. Some dogs showed improvement, with one dog experiencing a complete response for over five months and several others having partial responses or stable disease for a few months. However, many dogs eventually had their tumors progress. Overall, vinorelbine seemed to provide some benefit in managing these tumors, but more research is needed to fully understand its effectiveness.
People also search for: dog cancer treatment options · vinorelbine for dogs · mast cell tumor in dogs treatment
Abstract
OBJECTIVE: To evaluate the effectiveness of vinorelbine in the management of various malignant tumor types in dogs. DESIGN: Retrospective case series. ANIMALS: 58 dogs with malignant tumors, including pulmonary carcinoma (n = 31), histiocytic sarcoma (9), mast cell tumor (5), lymphoma (4), melanoma (2), and 7 other tumor types (1 each). PROCEDURES: Medical records of dogs treated with vinorelbine from December 1997 to December 2012 were reviewed for data regarding signalment, clinical signs, physical examination findings, clinicopathologic test results, diagnostic imaging results, vinorelbine doses and dose frequency, surgery and radiotherapy details when applicable, other chemotherapeutics administered, and outcomes. Descriptive, comparative, and survival statistics were computed for all dogs and for dogs by histologic subgroup of tumors. RESULTS: Vinorelbine was administered palliatively to 44 (76%) dogs. One (2%) dog had a complete response for 162 days, 5 (11%) dogs had a partial response for a median duration of 91 days, 19 (43%) dogs had stable disease for a median duration of 68 days, and 19 (43%) dogs developed progressive disease after a median duration of 21 days. Clinical benefit was more difficult to assess in the remaining 14 (24%) dogs that received vinorelbine as an adjuvant treatment. Overall median time to tumor progression was 103 days (range, 5 to 1,533 days). CONCLUSIONS AND CLINICAL RELEVANCE: Vinorelbine appeared to be effective in the treatment of several tumor types in dogs. Follow-up prospective studies of the clinical benefit of the drug in specific clinical scenarios will be necessary to support this conclusion.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25970220/